- Home
- NOTV
NOTV
Inotiv Inc.
as 02-21-2025 4:00pm EST
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | WEST LAFAYETTE |
| Market Cap: | 128.0M | IPO Year: | 1997 |
| Target Price: | $5.92 | AVG Volume (30 days): | 679.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.23 - $11.42 | Next Earning Date: | 02-05-2025 |
| Revenue: | $475,114,000 | Revenue Growth: | -18.81% |
| Revenue Growth (this year): | 6.37% | Revenue Growth (next year): | 5.74% |
Stock Insider Trading Activity of Inotiv Inc. (NOTV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leasure Robert Jr. | NOTV | President and CEO | Feb 18 '25 | Sell | $3.82 | 73,617 | $281,135.96 | 956,592 | |
| Freeman Jeffrey Brennan | NOTV | VP-Finance & Corp. Controller | Feb 18 '25 | Sell | $4.05 | 1,339 | $5,416.26 | 27,478 | |
| Taylor Beth | NOTV | Chief Financial Officer | Feb 18 '25 | Sell | $4.01 | 4,370 | $17,506.66 | 108,368 | |
| Leasure Robert Jr. | NOTV | President and CEO | Jan 31 '25 | Sell | $4.15 | 22,700 | $94,298.07 | 956,592 | |
| Sagartz John E | NOTV | Chief Strategy Officer | Jan 31 '25 | Sell | $4.48 | 2,118 | $9,478.90 | 709,929 | |
| Krupp Jeffrey Arthur | NOTV | Chief Human Resources Officer | Jan 31 '25 | Sell | $4.33 | 2,508 | $11,096.07 | 29,029 | |
| Taylor Beth | NOTV | Chief Financial Officer | Jan 31 '25 | Sell | $4.47 | 2,054 | $9,171.11 | 108,368 | |
| Landman David | NOTV | Director | Dec 19 '24 | Buy | $4.25 | 23,529 | $99,998.25 | 176,851 | |
| Beattie John Gregory | NOTV | Chief Operating Officer | Dec 10 '24 | Buy | $4.75 | 30,000 | $142,500.00 | 161,761 | |
| Brown Nigel | NOTV | Director | Dec 10 '24 | Buy | $4.26 | 7,500 | $31,950.00 | 65,537 |
Latest Inotiv Inc. News
NOTV Breaking Stock News: Dive into NOTV Ticker-Specific Updates for Smart Investing
GuruFocus.com
16 days ago
Inotiv Inc (NOTV) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...
GlobeNewswire
17 days ago
Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update
GlobeNewswire
a month ago
Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
MT Newswires
2 months ago
Inotiv Raises Another $3.6 Million From Sale of Additional Shares
GlobeNewswire
2 months ago
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
MT Newswires
2 months ago
Inotiv Raises Net Proceeds of $24 Million From Equity Offering
GlobeNewswire
2 months ago
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million
MT Newswires
2 months ago
Inotiv Prices 6 Million Share Offering at $4.25 Per Share
Compare NOTV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NOTV Inotiv Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.